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MicroRNAs (miRNAs) are evolutionary conserved, small non-coding RNA with size
ranging from 19 to 24 nucleotides. They endogenously regulate the gene expression at
the post transcriptional level either through translation repression or mRNA degradation.
MiRNAs have shown the potential to be used as a biomarker for the diagnosis,
prognosis, and therapy of infectious diseases. Many miRNAs have shown significantly
altered expression during infection. The altered expression of miRNA level in an infected
human can be identified by the use of advanced diagnostic tools. In this review, we
have highlighted the use of miRNA as an emerging tool for the identification of the
human infectious disease. Till date, several miRNAs have been reported as a molecular
biomarker in infectious diseases, such as miRNA-150 and miRNA-146b-5p in human
immunodeficiency virus (HIV); miRNA-122, miRNA-21, and miRNA-34a in hepatitis;
miRNA-361-5p and miRNA-29c in tuberculosis; miRNA-16 and miRNA-451 in malaria
and miRNA-181 in Helicobacter pylori infection. The diagnosis of infection with the help
of a biomarker is a non-invasive tool that has shown to have a key role in early diagnosis
of infection. The discovery of circulating miRNA in the blood of infected patients has the
potential to become a powerful non-invasive biomarker in coming future.
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INTRODUCTION
MicroRNAs (miRNAs) are evolutionary conserved, small non-coding RNA, playing a significant
role in controlling human gene expression. They consist of 19–24 nucleotides long sequence
and regulate nearly 30% of human gene expression at the post transcriptional level (Lewis et al.,
2005; Farazi et al., 2008). Statistically, up regulation of single miRNA can regulate the activity of
hundreds of genes (Lim et al., 2005; Grimson et al., 2007). Lin-4 was the first miRNA discovered
in Caenorhabditis elegans, revealing its role in the transformation of L1–L2 larval stage and the
normal adult structure development and its mutation leads to incapability for laying eggs (Chalfie
et al., 1981; Feinbaum and Ambros, 1999). After 7 years of the discovery of Lin4, the second
miRNA let-7 was discovered, again in C. elegans; which was associated with the developmental
timing (Reinhart et al., 2000). MiRNAs play an extensive role in the maintenance of the regulatory
signaling at the cellular level, which either provides protection from the disease or favors its
persistency by inducing protected or unprotected signaling pathways, respectively (Wang et al.,
2008).
Scientists have established a significant correlation between the miRNA and the cause of diseases
(Pandey et al., 2016); therefore, today several miRNAs are being utilized as molecular biomarkers
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for the diagnosis of human infectious diseases (Almeida et al.,
2011). During pathological conditions, alteration of a specific
miRNA than healthy control can be used as a biomarker to
predict the diseased condition (Figure 1). In this article, we
have highlighted the importance of circulating miRNAs in the
diagnosis of infectious diseases. In HIV infection, miRNA-
223, miRNA-382, miRNA-125b, and miRNA-28, targets the 3′
untranslated region (UTR) of the HIV-1 messenger RNA, while
miRNA-150 binds to Nef 3′ long terminal repeats (LTR) at 773
and 89 positions (Huang et al., 2007). In hepatitis, miRNA-
122 expression target the 5′ end of hepatitis C virus (HCV)
genome (Wahid et al., 2010). Altered expression of miRNA-
365, miRNA-483-5p, miRNA-22, miRNA-29c, miRNA-101, and
miRNA-320 are reported in tuberculosis and affect the mitogen-
activated protein kinases (MAPK) and transforming growth
factor beta (TGF-β) signaling to develop tuberculosis infection
(Zhang et al., 2013). However, significantly lower plasma level
of miRNA-16 and miRNA-451 has been reported in malaria
patients (Chamnanchanunt et al., 2015). MiRNA-181 targets
3′UTR region of tumor suppressor Krüppel-Like Factor (KLF)
encoding gene during Helicobacter pylori infection (Zabaleta,
2012). These altered miRNAs levels in human blood/serum
during different pathogenic infections can be used as a biomarker
in discrimination of human infectious diseases.
BIOGENESIS OF miRNA IN HUMAN
INFECTIOUS DISEASES
When hitherto infected vector bites to human, entry of a
number of pathogens in the human body takes place. As the
FIGURE 1 | MiRNA based diagnosis of human infectious diseases.
Colored ellipse represents the different steps of diagnosis. It include blood
(serum) collection from healthy and diseased persons followed by RT-qPCR,
miRNA profiling, comparative miRNA study leading to the diagnosis of
disease. Later on, patient could be recommended for the available treatment.
pathogen enters, they become active in the peripheral blood
and releases several associated factors for their protection. In
response to pathogenic activity several changes occur in the
cellular system; simultaneously, leading to the production of
the miRNAs controlling the diseased condition through cellular
signaling. During the miRNA development process, the non-
coding part of the host genome is transcribed by RNA polymerase
II to form the primary miRNA having a local hairpin structure.
Further, cropping of pri-miRNA by DROSHA (RNase III protein)
leads to the formation of precursor (pre) miRNA. Pre-miRNA
exported to the cytoplasm where it further processed by Dicer
(RNase III type endonuclease) to form an RNA duplex which is
subsequently loaded onto AGO1-4. Later on, passenger strand
of RNA duplex is discarded to form mature miRNA in complex
with AGO proteins (Ha and Kim, 2014). The resulting miRNA
binds to the mRNA sequence and inhibits the translation process
or degrades the target mRNA (Bartel, 2004; MacFarlane and
Murphy, 2010).
RESEARCH STUDIES ON miRNA IN
INFECTIOUS DISEASE
This review highlighted the importance of miRNAs in the
diagnosis of selected human infectious diseases caused by virus,
bacteria and parasites (Table 1) and the respective way of
diagnostics (Figure 1).
Human Immunodeficiency Virus (HIV)
Infection
Human Immunodeficiency Virus infection leads to the
development of an immunocompromised condition known
as Acquired Immune Deficiency Syndrome (AIDS). HIV, targets
to suppress cell mediated immunity, which leads to the decreases
in number of CD4+ T lymphocyte cells and finally, deterioration
of the immune power. HIV infected individuals have shown
varying expression of host specific miRNAs along with viral
miRNAs, which inhibit the post transcriptional gene regulation
in host cell (Bartel, 2004; Soifer et al., 2007). Research, analysis,
suggests that 62 different types of miRNAs were present in
peripheral blood mononuclear cells (PBMCs) of HIV/AIDS
infected human and among them only three miRNAs were
up regulated whereas the remaining 59 miRNAs were found
to be down regulated. Interestingly, miR-146b-5p, miR-223,
miR-150, miR-16, and miR-191 among the down regulated
miRNAs were found to be plentifully expressed in B and
T-lymphocyte, confirming a positive disease status (Houzet
et al., 2008). In HIV infection, increased expression of miRNA-
223, miRNA-382, miRNA-125b, and miRNA-28 targets the 3′
UTR of HIV-1 mRNA, which may subsequently decrease HIV
replication. MiRNA-150 binds to Nef 3′-LTR at 773 and 89
position to reduce the expression of PBMC oploid individuals.
MiRNA-223 interacts with Nef 3′-LTR at 408th residues of viral
protein (Huang et al., 2007). The PBMC miRNA-146b-5p and
miRNA-150 level was decreased in HIV/AIDS patient and an
individual with antiretroviral therapy (ART) resistance while
restoring with ART. The decreased levels of miRNA-146b-5p,
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TABLE 1 | Differential miRNA expression pattern in different infectious diseases.
S. No. Infectious disease Upregulated miRNA during
infection
Downregulated miRNA during
infection
Reference
1 HIV/AIDS miRNA-382,
miRNA-125b,
miRNA-28,
miRNA-21,
miRNA-122,
Let-7,
miRNA-34a,
miRNA-12,
miRNA-19,
miRNA-92b
miRNA-146b-5p,
miRNA-223,
miRNA-150,
miRNA-16,
miRNA-191,
miRNA-17-5p,
miRNA-20
Huang et al., 2007; Houzet et al., 2008;
Dai, 2011; Munshi et al., 2014;
Thapa et al., 2014
2 Hepatitis miRNA-122,
miRNA-34a,
miRNA-101,
Let-7b,
miRNA-196,
miRNA-448,
miRNA-149,
miRNA-638,
miRNA-199a,
miRNA-491
–
–
–
–
–
–
–
–
–
–
Cermelli et al., 2011; Fu et al., 2013;
Conrad and Niepmann, 2014
3 Tuberculosis miRNA-144,
miRNA-365,
miRNA-146
miRNA-361-5p,
miRNA-889,
miRNA-576-3p
Qi et al., 2012; Yi et al., 2012;
Song et al., 2015
4 Helicobactor pylori infection miRNA-223 miRNA-129-1-3p,
miRNA-129-2-3p
Li et al., 2012;
Sandoval-Borquez et al., 2015
5 Malaria miRNA-223,
miRNA-19b
miRNA-451,
miRNA-16
Goo et al., 2014;
Chamnanchanunt et al., 2015
6 Trypanosomiasis miRNA-193b,
miRNA-338
miRNA-199a-3p,
miRNA-27b,
miRNA-126
Lueong et al., 2013; Lueong, 2014
miRNA-16, miRNA-191, miRNA-150, and miRNA-223 in
PBMC compared to healthy individual provide the evidences
for HIV infection (Houzet et al., 2008). However, the higher
expression level of miRNA-21, miRNA-122 and lower expression
level of miRNA-223 can be utilized to discriminate between
HIV positive and HIV negative humans (Thapa et al., 2014).
MiRNA-17-5p and miRNA-20 down regulate the expression of
p300/CBP-associated factor (PCAF) histone acetyl-transferase,
can induce the inhibition of the HIV virus in the human body
(Munshi et al., 2014). MiRNA-222 can be used to distinguish
diffuse large B cell lymphoma or primary central nervous system
lymphoma (PCNSL), if the HIV-1 infected individual is not
affected by AIDS-NHL (Non-Hodgkin’s Lymphoma; Thapa
et al., 2014). HIV suspected individuals have shown the higher
level of miRNA-21 compared to healthy control, which is also up
regulated in activated B cells, and can be used to identify AIDS
related NHL infection. The up regulation of let-7, miRNA-34a,
and miRNA-12 provides a suitable environment to propagate the
HIV infection and can also be used as a biomarker. MiRNA-29a
and miRNA-29b targets the Nef 3′LTR/UTR viral gene at the 420
position and downregulates nef protein expression (Ahluwalia
et al., 2008; Sun et al., 2011). HIV-infected PCNSL patient has
shown a significantly increased level of miRNA-19, miRNA-
21, and miRNA-92b in cerebro-spinal fluid (CSF; Dai, 2011)
therefore, these miRNAs can also be used as a biomarker.
Hepatitis
Hepatitis is a viral infection of human liver that results in
swelling and inflammation. The symptoms include nausea,
vomiting, weight loss, abdominal pain, jaundice, dark yellow
urine, and fever. Acute hepatitis never show symptoms in the
early stage and may change into chronic hepatitis leading to
liver fibrosis, liver scarring, liver cancer, and increased level
of hepatocellular carcinoma (HCC). The hepatitis virus can
increase the level of a specific miRNA in the affected person’s
blood/serum. At present, several miRNAs namely miRNA-
122, miRNA-34A, miRNA-16, miRNA-21 have been reported
as biomarkers in hepatitis related HCC(Cermelli et al., 2011).
MiRNA-122 and miRNA-34a were significantly up-regulated
while the miRNA-21 level was found to be normal during HCV
infection.
Hepatic fibrosis, supported by the TGF-β signaling, promotes
expression of miRNA-21 but the decreased expression of miRNA-
21 suppresses the SMAD7 signaling. Therefore, miRNA-21 might
be a useful biomarker in hepatic fibrosis infection (Bihrer
et al., 2011). Secretions of enzymes and TGF-β from liver
cells are associated with higher expression of miRNA-34a and
miRNA-122, found to be helping in fibrosis development of
liver tissue. MiRNA-122 specifically binds to 5′ end of HCV
genome into the liver and encourages viral replication and
progression of infection. The expression of miRNA-101 was
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high in HCC infected individuals, can give the information
of hepatitis-B surface antigen in the liver (Fu et al., 2013).
MiRNA-122, miRNA-199a, miRNA-196, miRNA-448, and let-
7b was found to be expressed during hepatitis C infection
and regulate the pathogenicity. Circulating Let-7b, interacts
with the conserved NS5B coding sequence and 5′ UTR
region of the HCV genome, leading to the inhibition of
replication (Cheng et al., 2012). MiRNA-196 and miRNA-448
were found to be up-regulated in HCV infected individuals,
target the coding region (CORE and NS5A) of HCV genomic
RNA. Simultaneously, miRNA-149, miRNA-638, and miRNA-
491 were up-regulated due to HCV infection and enhance the
viral replication by inhibiting the AKT/PI3 kinase (Conrad
and Niepmann, 2014). Therefore, these miRNAs show the
great potential for their utilization as molecular markers to
diagnose of hepatitis viral infectious disease by non-invasive
methods.
Tuberculosis
Tuberculosis is a contagious and infectious disease caused by
Mycobacterium tuberculosis bacteria; which affects the human
lungs. It is of two types; latent or active tuberculosis. If a
person is infected with M. tuberculosis but lacks the symptoms
and do not feel sick, called latent tuberculosis, but a person
with M. tuberculosis infection and its respective symptoms,
represents active tuberculosis. Recent research on tuberculosis
significantly offers beneficial information about miRNAs as a
biomarker for the investigative purposes. Pulmonary tuberculosis
infected individuals have shown elevation in 92 miRNAs in
serum. Among which 59 miRNAs were up regulated and
rest of 23 miRNAs were down regulated as compared to
healthy controls (Yi et al., 2011). MiRNA-144 was found to
be highly expressed in the PBMC compared to miRNA-361-5P,
miRNA-889, and miRNA-576-3p that were significantly down
regulated in active tuberculosis patients. However, increased
level of miRNA-361-5p, miRNA-889, and miRNA-576-3p have
been reported in tuberculosis infected serum as non-invasive
molecular biomarker for rapid diagnosis and prevention of
tuberculosis infection (Qi et al., 2012). Alteration in miRNA-
378, miRNA-483-5p, miRNA-22, miRNA-29c, miRNA-101,
and miRNA-320 are specific for pulmonary tuberculosis and
non-tuberculosis infections. These miRNAs are deferentially
expressed and affect MAPK & TGF-β signaling, which can be
used for the identification of tuberculosis infection. MiRNA-378
and miRNA-101 target the MAPA1 signaling while miRNA-
483-5p, miRNA-320, miRNA-22 affect AKT-3, and BCL9L
signaling to develop tuberculosis infection (Zhang et al., 2013).
Upregulated miRNA-365 has shown inhibitory effect against IL-
6 signaling by binding at its 3′UTR in tuberculosis infection
(Song et al., 2015). MiRNA-146 has shown 3.34 fold over
expression as compared to healthy individuals (Yi et al., 2012).
Researchers have identified specific miRNAs (miRNA-29a and
miRNA-22), that were used to discriminate between active and
latent tuberculosis infection (Zhang et al., 2013). MiRNA-29 was
considered to control the innate and acquired immune response
by targeting IFN-γ in pulmonary tuberculosis (Wiwanitkit and
Wiwanitkit, 2012) therefore, nominated as a biomarker. These
miRNAs can be used as a molecular biomarker for the diagnostic
and prognostic by the Taqman Low Density Assay (Qi et al.,
2012).
Helicobacter pylori Infection
Helicobacter pylori are spiral shaped bacteria that mainly grow
inside the gastrointestinal tract and is capable of infecting the
inner lining of the stomach. Generally, infection of H. pylori
is harmless, but in some cases it is responsible for the ulcer
of stomach and small intestine. H. pylori infection causes ulcer,
nausea, vomiting, unexpected weight loss and abdominal pain.
However, some other facet of H. pylori infection was also
reported that its colonization of the stomach is the major cause
of gastric cancer and gastric mucosa associated lymphoid tissue
(MALT; Parsonnet et al., 1991; Eslick et al., 1999; Uemura et al.,
2001). MiRNAs have also shown their role in gastric cancer
and have been reported as a potential molecular biomarker
(Zabaleta, 2012). MiRNA-223, miRNA-22, miRNA-218, and
miRNA-25 has been found to be associated with metastasis
and gastric cancer. MiRNA-223 over expression represses the
gastric cancer and inhibits the exosomes transfer of metastatic
cells in another part of the body. MiRNA-218 has found to
be lowering the cell development and invasion as compared to
healthy control (Li et al., 2012). MiRNA-181 interacts with the 3′
UTR region of the tumor suppressor KLF gene and have ability
to inhibit the apoptosis of tumor cells (Zabaleta, 2012). Current
research analysis on miRNAs (miRNA-10b, miRNA-21, miRNA-
223, miRNA-338, let-7a, miRNA-30a-5p and miRNA-126) in
gastric cancer have been noted to show a positive correlation with
the identification and diagnosis of early cancer stages (Li et al.,
2012). Knockdown of the miRNA-21 promotes the apoptosis and
reduced cell proliferation (Zhang et al., 2008). MiRNA-129-1-
3p and miRNA-129-2-3p have shown down-regulation in gastric
cancer patient as compared to the healthy control therefore these
miRNAs were responsible for the cell proliferation and cell cycle.
Furthermore, altered expression of 16 miRNAs was reported on
H. pylori mediated gastric cancer condition. Altered expression
of miRNA-221, miRNA-744, and miRNA-376c significantly give
a positive identification of the disease (Sandoval-Borquez et al.,
2015). MiRNA-142-5p and miRNA-155 have shown their role
as a molecular biomarker for gastric MALT (Saito et al., 2012).
On the basis of above reports, we can conclude that these
aforementioned miRNA can be used as a potential biomarker for
the identification of the H. pylori mediated gastric cancer and
gastric MALT.
Malaria
Malaria is a vector borne infectious disease caused by protozoan
parasites namely Plasmodium vivax, P. faliciparum, P. malariae,
P. knowlesi, and P. ovale. Among them P. falciparum is
considered to be more fatal as it leads to cerebral malaria,
if proper medication has not been given. Malarial parasite
causes high fever, headache, extreme tiredness, clogging blood
vessels, vomiting, and rupture of blood vessels. Since, the
symptoms appear after 15 days of infection; therefore we
cannot diagnose early infection by available molecular tools.
Infection of the malarial parasite in human could potentially
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alter the expression of erythrocytic miRNA in the blood and
these miRNAs can be diagnosed by the molecular diagnostic
tool like quantitative reverse transcriptase polymerase chain
reaction (RT-qPCR), microarray profiling and next generation
sequencing can give an indication of infection. MiRNA-451
and miRNA-16 have been found to be down regulated in
blood/serum of malaria patients as compared to healthy control.
The first reason behind the downregulation of miRNA is
the degradation of red blood cells (RBC) miRNA after the
Plasmodium infection (LaMonte et al., 2012). The second reason
behind this downregulation is the clearance of miRNA in case
of hypersplenism during malaria infection, therefore it may
increase the RBC destruction by the spleen (Buffet et al.,
2011). Furthermore, lower expression of these two miRNAs
(miRNA-451 and miRNA-16) significantly gives information
about the parasite load in the blood (Chamnanchanunt
et al., 2015). Sickle cell erythrocyte infected person may
have higher expression of the miRNA-451 and let-7i in
blood (Eridani, 2013). Healthy person infected by malaria
parasite has shown higher expression of miRNA-223 and
miRNA-19b in normal RBC cells in blood (Goo et al.,
2014).
Trypanosomiasis
Trypanosomiasis (sleeping sickness) is an infectious disease
caused by protozoan parasitic of genus Trypanosomes. The
control of trypanosomiasis infection cannot be done by early
diagnosis as symptoms do not appear generally in the early
stages of infection. Levels of miRNAs (miRNA-199a-3p, miRNA-
27b, and miRNA-126) have been noted significantly decreased
in humans infected by Trypanosoma brucei gambiense as
compared to healthy individuals. These miRNA deregulate the
signaling of toll like receptor and NF-kB after the infection
of Trypanosoma (Lueong, 2014). Therefore, the molecular
biomarker such as miRNAs can be used to identify the
infection of the trypanosomes or sleeping sickness using
peripheral blood leukocytes. However, trypanosomiasis patients
have shown the higher expression level of miRNA-193b
and miRNA-338 compared to control (Lueong et al., 2013).
At present time available molecular tools are very invasive,
less sensitive for detection of trypanosomiasis infection. So
by using miRNA based molecular biomarker, one can give
significant positive information about the infection at the early
stage.
CHALLENGES OF miRNA AS A
MOLECULAR BIOMARKER
Presently, only few standardized procedures are available for the
isolation and characterization of specific miRNA. Experimental
research and its observation have shown that small interfering
RNA, premature miRNAs, and transfer RNA may interfere
with specific miRNA during the process of isolation and
characterization. Therefore, this interference leads to the false
positive result, which should be taken care during diagnosis.
Small non-coding miRNA needs a carrier molecule for extraction,
such as long RNA for precipitation of particular miRNA. The
necessity of the large amount of RNA input for the northern
blot technique can generate difficulties in the quantification of
the miRNA. RT-qPCR, microarray profiling and next generation
sequencing have been found to be useful for the identification of
novel miRNA. Characterization of miRNA should be done by an
experienced researcher having a good knowledge of molecular
biology as well as Bioinformatics. The available tools of miRNA
characterization are very expensive; therefore everyone cannot
afford this diagnostic tool. During the course of the experiment
one should need to take extra precautions to avoid experimental
contamination and data interpretation issues which can alter the
level of miRNA and can provide false results.
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